Current filters:


Popular Filters

1970 to 1994 of 2218 results

“Black box” warning for Seattle Genetics’ Adcetris


US biotech Seattle Genetics (Nasdaq: SGEN) saw its shares fall 5.2% to $17.49 on Friday, after the company…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

A lot of user fee issues in USA


2012 has only just begun, but the US Congress, the Food and Drug Administration and several health care…

BiotechnologyGenericsNorth AmericaPharmaceuticalPoliticsRegulation

Biogen Idec prepares for multiple launches in coming years


US biotech firm Biogen Idec (Nasdaq: BIIB) outlined its plans for driving the continued strong commercial…

Biogen IdecBiotechnologyMarkets & MarketingResearch

Threats to US biomedical industry viewed by CEOs


Access to capital, a burdensome and uncertain regulatory environment and lack of innovation and productivity…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

EMA opens public consultation on cancer drugs evaluation


A public consultation on the revised guideline on the evaluation of human anticancer medicines has been…


2011 a bumper year for Pharma, Biotech and Generics M&A


Although there were few multi-billion dollar deals, 2011 turned into a bumper year for the number of…

BiotechBiotechnologyGenericsMergers & AcquisitionsPharmaceutical

Pharmaceutical M&A deals in 2011


Details for the 129 M&A announcements recorded by The Pharma Letter are provided in the full table

BiotechGenericsMergers & AcquisitionsPharmaceutical

Another mega deal for FORMA Therapeutics


Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma…

BiotechnologyFORMA TherapeuticsJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Hospira progresses biosimilar Epogen


USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Human Genome Sciences’ Benlysta sales disappoint


US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday…

BenlystaBiotechnologyFinancialHuman Genome SciencesMarkets & MarketingRare diseasesraxibacumab

Xenon in $646 million deal with Roche unit


Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

LEO Pharma in over $300 million deal for psoriasis therapy


Privately-held Danish drugmaker LEO Pharma A/S has signed a multi-million dollar in-licensing deal with…

BiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalVirobay

Dendreon upbeat on Provenge sales


US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Drugmakers taking steps to improve R&D productivity, says Tufts CSDD


Even though pharmaceutical companies are pursuing innovative approaches to increase the pace and reduce…


Bionomics in $345 million CNS deal with Ironwood


Australian biotech firm Bionomics (ASX: BNO) entered into a collaboration, research and licensing agreement…

BionomicsBiotechnologyIronwood PharmaceuticalsLicensingNeurologicalPharmaceuticalResearch

Smith & Nephew to spin-out biologics and clinical therapies unit


Texas, USA-based venture capital firm Essex Woodlands has entered into a strategic partnership with the…

BiotechnologyBioventusMergers & AcquisitionsSmith & Nephew

Isis Pharma could earn $299 million from Biogen Idec deal


US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Many NIH-funded clinical trials go unpublished


In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed…


Phylogica signs deal with Johnson & Johnson unit


Australian peptide drug discovery company Phylogica (ASX: PYC) has entered into a collaboration and option…

BiotechnologyFinancialJanssen BiotechJohnson & JohnsonLicensingPharmaceuticalPhylogica

Biotech predictions for 2012 from sector specialist Steven Burrill


As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

1970 to 1994 of 2218 results

Back to top